Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.

The Journal of clinical investigation - 14 Mar 2024

Vaccaro Kyle, Allen Juliet, Whitfield Troy W, Maoz Asaf, Reeves Sarah, Velarde José, Yang Dian, Meglan Anna, Ribeiro Juliano, Blandin Jasmine, Phan Nicole, Bell George W, Hata Aaron N, Weiskopf Kipp

Abstract excerpt

Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown, and ongoing studies suggest they may be most effective when used in combination with other anticancer agents. Here, we developed an unbiased, high-throughput screening platform to identify drugs that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Macrophages

Share to MAP Kinase Signaling System

Share to Molecular Targeted Therapy

Share to Phagocytosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 38483480
DOI: 10.1172/JCI169315
PMCID: PMC11060739

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.PMID 38483480Read ↗

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionSemantic proximity Read ↗

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.Semantic proximity Read ↗

CD47 predominates over CD24 as a macrophage immune checkpoint in cancerSemantic proximity Read ↗

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα AxisSemantic proximity Read ↗

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.Semantic proximity Read ↗

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunitySemantic proximity Read ↗

CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer.Semantic proximity Read ↗

Macrophages, Inflammation, and Lung Cancer.Semantic proximity Read ↗

Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.Semantic proximity Read ↗

Recent Advances of Tumor Therapy Based on the CD47-SIRPα AxisSemantic proximity Read ↗

Organoid modeling of tumor-associated macrophages reveals phagocytosis checkpoint blockade-induced conversion to an immunosuppressive SPP1+ phenotypeSemantic proximity Read ↗

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.